CN107028875A - A kind of antibacterial polyaminoacid gel and preparation method thereof - Google Patents
A kind of antibacterial polyaminoacid gel and preparation method thereof Download PDFInfo
- Publication number
- CN107028875A CN107028875A CN201710450875.5A CN201710450875A CN107028875A CN 107028875 A CN107028875 A CN 107028875A CN 201710450875 A CN201710450875 A CN 201710450875A CN 107028875 A CN107028875 A CN 107028875A
- Authority
- CN
- China
- Prior art keywords
- polyaminoacid
- antibacterial gel
- gel
- antibacterial
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001308 poly(aminoacid) Polymers 0.000 title claims abstract description 166
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 139
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 238000001879 gelation Methods 0.000 title description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000003755 preservative agent Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 5
- 239000008213 purified water Substances 0.000 claims description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 19
- 235000011187 glycerol Nutrition 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 17
- 229920002125 Sokalan® Polymers 0.000 claims description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 229960001631 carbomer Drugs 0.000 claims description 12
- -1 methyl para Toluic Acid Chemical compound 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- 229910021538 borax Inorganic materials 0.000 claims description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 5
- 229920002674 hyaluronan Chemical class 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 230000003204 osmotic effect Effects 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000004328 sodium tetraborate Substances 0.000 claims description 5
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Chemical class OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 4
- 241000206575 Chondrus crispus Species 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 4
- 229960000458 allantoin Drugs 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 235000004426 flaxseed Nutrition 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 229950005134 polycarbophil Drugs 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluenecarboxylic acid Natural products CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 claims description 3
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 210000002268 wool Anatomy 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 239000001913 cellulose Chemical class 0.000 claims description 2
- 229920002678 cellulose Chemical class 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- LLJZKKVYXXDWTB-UHFFFAOYSA-N acetic acid;sodium Chemical compound [Na].[Na].CC(O)=O LLJZKKVYXXDWTB-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 125000003916 ethylene diamine group Chemical group 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 208000004210 Pressure Ulcer Diseases 0.000 abstract description 4
- 208000019751 Anorectal disease Diseases 0.000 abstract description 3
- 208000015815 Rectal disease Diseases 0.000 abstract description 3
- 206010053615 Thermal burn Diseases 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 206010040872 skin infection Diseases 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 118
- 241000588724 Escherichia coli Species 0.000 description 42
- 241000191967 Staphylococcus aureus Species 0.000 description 42
- 231100000263 cytotoxicity test Toxicity 0.000 description 32
- 239000000243 solution Substances 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 20
- 230000000845 anti-microbial effect Effects 0.000 description 17
- 210000002950 fibroblast Anatomy 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 229920001661 Chitosan Polymers 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 231100000135 cytotoxicity Toxicity 0.000 description 15
- 230000003013 cytotoxicity Effects 0.000 description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 238000006384 oligomerization reaction Methods 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 0 CC*(C)(C(C(C)C(C)C)C1[C@@](C)CCCC1)C1C2C1CCC*2 Chemical compound CC*(C)(C(C(C)C(C)C)C1[C@@](C)CCCC1)C1C2C1CCC*2 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RWSBQZUWRUIRJD-OWTMBLHMSA-N CCC1C2NCCC[C@@H]2C1C Chemical compound CCC1C2NCCC[C@@H]2C1C RWSBQZUWRUIRJD-OWTMBLHMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920003656 Daiamid® Polymers 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical class [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a kind of polyaminoacid antibacterial gel, polyaminoacid antibacterial gel includes the component of following percentage by weight：0.01 50% polyaminoacid, 0.01 90% gel-type vehicle, 0 20% NMF, 0 1% preservative agent, surplus is water.The invention also discloses the preparation method of above-mentioned polyaminoacid antibacterial gel.The obtained polyaminoacid gel of the present invention is in combination with advantage of both polyaminoacid material and gel, with good antibiotic property and biocompatibility, available for the biologic medical field such as diabetic skin infection, burn, scald, bedsore infection, scytitis, mouth infection, gynecological disease or anorectal disease.Bacteriostasis rate >=95% of polyaminoacid antibacterial gel produced by the present invention, far above like product.
Description
Technical field
The present invention relates to a kind of antibacterial gel and preparation method thereof, more particularly, to a kind of antibacterial polyaminoacid gel and its
Preparation method.
Background technology
At present, gel is widely used in the infectivities such as treatment surgery wound, scytitis, gynaecological imflammation, rectum inflammation
Position and chronic refractory wound.The antimicrobial component contained in many gel-like dressing or medicine has very big side effect.And gather
Amino acids material is because of the structure of its analogous protein, the advantages of possessing good biocompatibility, biological degradability, extensively
Applied to the biologic medical such as medicine controlled releasing, organizational project, gene therapy field.
Chinese patent application CN105694030A discloses the hydridization antibacterial water that a kind of oligomerization propylhomoserin is combined with sodium alginate
Gel.But its preparation method is complicated, production cost is high, and large-scale application is difficult, and its bacteriostasis rate only up to reach
90%.
The content of the invention
The invention solves the problems that first technical problem be to provide a kind of polyaminoacid antibacterial gel, the polyaminoacid coagulates
Glue can be used in combination with advantage, such as good antibiotic property and biocompatibility of both polyaminoacid material and gel
It is raw in diabetic skin infection, burn, scald, bedsore infection, scytitis, mouth infection, gynecological disease or anorectal disease etc.
Thing medical field；Bacteriostasis rate >=95% of polyaminoacid antibacterial gel produced by the present invention.
The invention solves the problems that second technical problem be to provide a kind of preparation side of above-mentioned polyaminoacid antibacterial gel
Method.The preparation method is simple, suitable for mass production.
To solve above-mentioned first technical problem, the present invention uses following technical proposals：
A kind of polyaminoacid antibacterial gel, polyaminoacid antibacterial gel includes the component of following percentage by weight：0.01-
50% polyaminoacid, 0.01-90% gel-type vehicles, 0-20% NMFs, 0-1% preservative agents, surplus is water.
Further, the polyaminoacid is the structure such as following formula (I)：
It is abbreviated as R- [(M)m-(N)n]z,
In formula (I), R is any one in structure as shown below：
(PAMAM is daiamid),(a is the degree of polymerization of chitosan),
In formula (I), R1For any one in structure as shown below：
In formula (I), R2For any one in structure as shown below：
In formula (I), m and n are respectively polyaminoacid repeat unit M and repeat unit N number of repeat unit；Z is (M) m-
(N) n number of repeat unit；M, n, z are positive integer, m=5-10000, n=0-1000, z=1-100；" * " is R, R1、R2With
The chemical bond chalaza of its adjacent group.
Preferably, R is worked as2During for any one in structure as shown below：
Then m × z ＞ 50% (m × z+n × z)；
That is, repeat unit M sum is more than the 50% of repeat unit M and repeat unit N summations.
Further, percentage by weight of the polyaminoacid in polyaminoacid antibacterial gel is 0.1-50%, or 1-
50%, or 5-50%, or 10-50%, or 15-50%, or 20-50%, or 25-50%, or 30-50%, or 35-50%, or
40-50%, or 45-50%, or 0.1-40%, or 1-40%, or 5-40%, or 15-40%, or 20-40%, or 25-40%,
Or 30-40%, or 35-40%, or 0.1-30%, or 1-30%, or 5-30%, or 10-30%, or 15-30%, or 20-
30%, or 25-30%, or 0.1-20%, or 1-20%, or 5-20%, or 10-20%, or 15-20%, or 0.1-10%, or
1-10%, or 5-10%.
Further, the gel-type vehicle be selected from carbomer, Chitosan-phospholipid complex, alginic acid and its salt, trehalose,
Hyaluronic acid and its salt, cellulose derivative, xanthans, gelatin, collagen, carragheen, Arabic gum, flaxseed gum,
One or more in Polycarbophil, polyvinylpyrrolidone and polyvinyl alcohol.
Preferably, percentage by weight of the gel-type vehicle in polyaminoacid antibacterial gel is 0.1-90%, or 0.1-
80%, 0.1-70%, 0.1-60%, 0.1-50%, 0.1-40%, 0.1-30%, 0.1-20%, 0.1-10%, 0.1-5%,
0.5-90%, 0.5-80%, 0.5-70%, 0.5-60%, 0.5-50%, 0.5-40%, 0.5-30%, 0.5-20%, 0.5-
10%, 0.5-5%.
Further, the NMF is selected from glycerine, sorbierite, propane diols, butanediol, pentanediol, glycerine and positive fourth
One or more in alcohol.
Preferably, percentage by weight of the NMF in polyaminoacid antibacterial gel is 1-20%, or 1-18%, or
1-16%, or 1-14%, or 1-12%, or 3-20%, or 3-18%, or 3-16%, or 3-14%, or 3-12%, or 5-
20%, or 5-18%, or 5-16%, or 5-14%, or 5-12%, or 7-20%, or 7-18%, or 7-16%, or 7-14%,
Or 7-12%, or 9-20%, or 9-18%, or 9-16%, or 9-14%, or 9-12%.
Further, the preservative agent is selected from disodium ethylene diamine tetraacetate, sodium benzoate, potassium sorbate, citric acid, oxybenzene
One or more in ethyl ester, methyl para Toluic Acid, parabens and its sodium salt, the golden ethyl ester of Nepal.
Preferably, percentage by weight of the preservative agent in polyaminoacid antibacterial gel is 0.1-1%, or 0.1-
0.9%, or 0.1-0.8%, or 0.1-0.7%, or 0.1-0.6%, or 0.3-0.9%, or 0.3-0.8%, or 0.3-
0.7%, or 0.3-0.6%, or 0.4-0.9%, or 0.4-0.8%, or 0.4-0.7%, or 0.4-0.6%.
Further, other additives can also be included in the polyaminoacid antibacterial gel.
Preferably, other additives include one kind in nutritional agents, solubilizer, pH adjusting agent and osmotic pressure regulator
Or it is a variety of.
Preferably, the nutritional agents is selected from fibroblast growth factor, epithelical cell growth factor, platelet derived growth
One or more in the factor, collagen and allantoin；Preferably, nutritional agents weight in polyaminoacid antibacterial gel
Percentage is 0.003-0.007%；
Preferably, the solubilizer is selected from polyethylene glycol, poloxamer, tween, polyoxyethylene wool alcohol ether, lauryl alcohol and gathered
One or more in oxygen vinethene, polyacrylic acid glycerol ester and ethanol；Preferably, the solubilizer is solidifying in polyaminoacid antibacterial
Percentage by weight is 0.04-0.06% in glue；
Preferably, the pH adjusting agent is selected from alkaline conditioner and acid regulator；Wherein, alkaline conditioner is three ethanol
One or more in amine, sodium hydroxide and sodium citrate, acid regulator is one in hydrochloric acid, acetic acid, lactic acid and citric acid
Plant or a variety of, it is preferable that alkaline matter percentage by weight in polyaminoacid antibacterial gel is 0.1-0.3%, acid
Matter percentage by weight in polyaminoacid antibacterial gel is 0.8-1.2%.
Preferably, one or more of the osmotic pressure regulator in sodium chloride, boric acid and borax；Preferably, institute
It is 0.8-1.2% to state osmotic pressure regulator percentage by weight in polyaminoacid antibacterial gel.
Further, the water is purified water.
To solve above-mentioned second technical problem, the preparation method of the above-mentioned polyaminoacid antibacterial gel of the present invention, including
Following steps：
S1, polyaminoacid is dissolved in purified water；
S2, gel-type vehicle, NMF, preservative agent and other additives are mixed with purifying after water-swellable dissolving respectively, then
The obtained polyaminoacid solution of step S1 is mixed with it, polyaminoacid antibacterial gel of the present invention is made.
The present invention has the advantages that：
The obtained polyaminoacid gel of the present invention is in combination with advantage of both polyaminoacid material and gel, with good
Good antibiotic property and biocompatibility, available for diabetic skin infection, burn, scald, bedsore infection, scytitis, oral cavity
The biologic medical fields such as infection, gynecological disease or anorectal disease.The bacteriostasis rate of polyaminoacid antibacterial gel produced by the present invention >=
95%, far above like product, and the preparation method of the present invention is simple, suitable for mass production.
Embodiment
In order to illustrate more clearly of the present invention, with reference to preferred embodiment, the present invention is described further.Ability
Field technique personnel should be appreciated that following specifically described content is illustrative and be not restrictive, and this should not be limited with this
The protection domain of invention.
Embodiment 1
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 50 |
| Carbomer | 0.01 |
| Edible sodium hydroxide | 0.004 |
| Glycerine | 2 |
| Ethyl hydroxy benzoate | 0.2 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) by carbomer dispersion in purified water, it is fully swelled, add edible sodium hydroxide, regulation pH value is 8,
Glycerine and ethyl hydroxy benzoate are added, carbomer gel matrix is obtained；
(3) the polyaminoacid solution for obtaining step (1) is added in the carbomer gel matrix that step (2) is obtained, and is mixed,
The polyaminoacid antibacterial gel for treating gynecological external use is made.
The antibacterial gel establishing criteria GB15979-2002 obtained to the present embodiment《Disposable Sanitary Accessory health mark
It is accurate》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.99%th, 99.99%, cytotoxicity is 0 grade.
Embodiment 2
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 0.01 |
| Carbomer | 7 |
| Propane diols | 0.1 |
| Ethanol | 40 |
| Glycerine | 0.05 |
| Ethylparaben | 1 |
| Triethanolamine | 0.1 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) by carbomer dispersion in purified water, it is made fully to be swelled；
(3) ethylparaben is added in ethanol, dissolved, add propane diols, glycerine, triethanolamine, pH value control
For 4, mixing；
(4) solution for obtaining step (1) and (3) is added in the solution that step (2) is obtained, and is mixed, and is made for treating
The local polyaminoacid antibacterial gel of anal intestine.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
97.20%th, 95.0%
Embodiment 3
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 10 |
| Carbomer | 1 |
| Chitosan | 10 |
| Propylene Glycol chitosan | 10 |
| Sodium cellulose glycolate | 4 |
| Glycerine | 8 |
| Sodium benzoate | 0.001 |
| Hydrochloric acid | 0.1 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) pH value of solution that step (1) is obtained is adjusted to 6.0 with 1mol/L watery hydrochloric acid, adds chitosan and methyl second two
Alcohol chitosan, mixes, obtains mixed liquor；
(3) carbomer, sodium cellulose glycolate, benzoic acid and glycerine are added on the basis of the mixed liquor that step (2) is obtained,
Mix, the polyaminoacid antibacterial gel for treating vaginitis is made.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.80%th, 99.20%, cytotoxicity is 0 grade.
Embodiment 4
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 1 |
| Chitosan | 0.2 |
| Acetic acid | 3 |
| Gelatin | 15 |
| Lactic acid | 1 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) chitosan is added mass concentration in 3% acetum, to be completely dissolved it；
(3) gelatin is dissolved in purified water, heated under the conditions of 30 DEG C, mixed；
(4) solution for obtaining step (1) and (2) is added in the solution that step (3) is obtained, and is mixed, is adjusted with lactic acid solution
It is 6.5 to save pH, and the polyaminoacid antibacterial gel for treating the surface of a wound is made.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.65%th, 99.32%, cytotoxicity is 0 grade.
Embodiment 5
Polyaminoacid antibacterial gel component is constituted：
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) chitosan (molecular weight 100,000) is dissolved in purified water, adds glacial acetic acid, mixed to being completely dissolved；Add
Gelatin, puts and is heated on 75 DEG C of water-bath, is completely dissolved to gelatin；
(3) solution that step (1) is obtained is added in the solution that step (2) is obtained, dissolving is evenly stirred until, pH controls are
5, it is made for treating the poly- of chronic wounds (bedsore, diabetic foot ulcer, lower limb vascular ulcer and I, the blister burn surface of a wound etc.)
Amino acid antibacterial gel.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.72%th, 97.34%, cytotoxicity is 0 grade.
Embodiment 6
Polyaminoacid antibacterial gel component is constituted：
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) chitosan is added in purified water, is adjusted using acetic acid, it is fully dissolved；
(3) take poloxamer to be added in absolute ethyl alcohol, dissolve, add Dodecyl Polyoxyethylene Ether, propane diols, sorb
Alcohol, is mixed；
(4) solution under agitation obtaining step (1) and (3) is added in the solution that step (2) is obtained in thread, is mixed
It is even, the polyaminoacid antibacterial gel for treating gynaecology is made.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.50%th, 99.10%, cytotoxicity is 0 grade.
Embodiment 7
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 10 |
| Polymer chitosan | 2 |
| Low molecular chitosan | 2.5 |
| Acetic acid | 4 |
| Polyoxyethylene wool alcohol ether | 1 |
| Carragheen | 4 |
| Methyl para Toluic Acid | 0.01 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) in the purified water containing acetic acid, polymer chitosan (molecular weight 60 × 10 is added4Da, deacetylation 88%)
Polyoxyethylene lanonol is added after sugared (molecular weight 800Da, deacetylation 100%), stirring and dissolving, homogenizing with low molecular chitosan
Ether, stirs, and obtains a kind of composite solution of chitosan-containing.
(3) purified water is heated to 90 DEG C of temperature, then adds carragheen, stirring and dissolving obtains a kind of carrageenan solutions；
(4) solution for obtaining step (1) and (2) is added in the solution that step (3) is obtained, and is mixed, and is made for controlling
Treat the polyaminoacid antibacterial gel of the surface of a wound.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.99%th, 99.96%, cytotoxicity is 0 grade.
Embodiment 8
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 5 |
| Sodium alginate | 90 |
| Poloxamer | 1 |
| Polyethylene glycol | 1 |
| Borax | 1 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) sodium alginate or potassium alginate, poloxamer, polyethylene glycol are scattered in purified water, adding borax makes it
Mix；
(3) solution for obtaining step (1) is added in the solution that step (2) is obtained, and is mixed, and is made for treating the surface of a wound
Polyaminoacid antibacterial gel.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.95%th, 99.45%, cytotoxicity is 0 grade.
Embodiment 9
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 5 |
| Calcium alginate | 90 |
| Tween | 0.05 |
| Citric acid | 1 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) calcium alginate is scattered in purified water, adds tween and citric acid and mix；
(3) solution for obtaining step (1) is added in the solution that step (2) is obtained, and is mixed, and is made for treating the surface of a wound
Polyaminoacid antibacterial gel.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.82%th, 99.00%, cytotoxicity is 0 grade.
Embodiment 10
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 30 |
| Trehalose | 10 |
| Xanthans | 10 |
| Butanediol | 20 |
| Potassium sorbate | 0.1 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) trehalose is mixed with purified water, is heated to 90 DEG C, be incubated 30min；
(3) xanthans and propane diols are mixed, is heated to 90 DEG C of emulsifications；
(3) solution for obtaining step (1) and (2) is added in the emulsion that (3) are obtained, and is mixed, is down to room temperature, is made and is used
In the polyaminoacid antibacterial gel of the treatment surface of a wound.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.99%th, 99.99%, cytotoxicity is 0 grade.
Embodiment 11
Polyaminoacid antibacterial gel component is constituted：
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) hyaluronic acid, the epidermal cell modified Sodium Hyaluronate (40~1,000,000 Da), VE-succinate are given birth to
The long factor, vitamin C are added in the solution that step (1) is obtained, and are mixed to dissolving；
(3) pentanediol, glycerine and transparent xanthan gum are added under agitation to mix to dissolving, are obtained homogeneous system, are used phosphorus
Mixture pH of latex gel is adjusted to 4.5 ± 0.5 by sour disodium hydrogen-citric acid buffer system, is made for the poly- for the treatment of vaginitis
Amino acid antibacterial gel.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.90%th, 99.40%, cytotoxicity is 0 grade.
Embodiment 12
Polyaminoacid antibacterial gel component is constituted：
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) borax and boric acid are dissolved in 0.9% sodium chloride solution, adds polyvinyl alcohol and polyethylene glycol, fully
Mixing is warming up to 121 DEG C of 60 min of insulation；
(3) it is cooled to room temperature and adds the solution that step (1) is obtained, is circulated by 20-20 DEG C to 37 DEG C of multigelations
Gel is built, is sufficiently cleaned with sterile saline sodium chloride, the poly- amino for treating burn wound reparation is made
Sour antibacterial gel.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.65%th, 99.22%, cytotoxicity is 0 grade.
Embodiment 13
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 10 |
| Polycarbophil | 1.5 |
| Carbomer | 0.375 |
| Disodium ethylene diamine tetraacetate | 0.02 |
| Chitosan | 1.25 |
| Glycerine | 10 |
| Triethanolamine | 0.43 |
| Methyl p-hydroxybenzoate | 0.375 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) Polycarbophil, carbomer and glycerine are mixed, stirring obtains pasty liquid；
(3) chitosan is added in step (1), adds disodium ethylene diamine tetraacetate and methyl p-hydroxybenzoate, stirring
Dissolving；
(4) pasty liquid for obtaining step (2) is added in the solution that step (3) is obtained, and is mixed, is used triethanolamine solution
Its pH value is adjusted to 3.8~4.4, the polyaminoacid antibacterial gel for treating vagina is made.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.65%th, 99.32%, cytotoxicity is 0 grade.
Embodiment 14
Polyaminoacid antibacterial gel component is constituted：
| Composition | Weight ratio/% |
| Polyaminoacid | 10 |
| Collagen | 1 |
| Hyaluronic acid | 0.4 |
| Allantoin | 0.05 |
| Platelet derived growth factor | 0.05 |
| Glycerine | 4 |
| Polyacrylic acid glycerol ester | 0.5 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid, glycerine, polyacrylic acid glycerol ester are dissolved in purified water；
(2) hyaluronic acid, allantoin, platelet derived growth factor, collagen are added in step (1), mixed, is made
The polyaminoacid antibacterial gel healed for treat wound.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.55%th, 99.12%, cytotoxicity is 0 grade.
Embodiment 15
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 25 |
| Arabic gum | 5 |
| Flaxseed gum | 2 |
| Fibroblast growth factor | 0.05 |
| Hydroxypropyl cellulose | 3 |
| N-butanol | 5 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) Arabic gum, flaxseed gum are dissolved in purified water；
(3) hydroxypropyl cellulose is dissolved in purified water；
(4) solution for obtaining step (1), (2) and (3) is stirred in the case where adding n-butanol, adds fibroblast life
The long factor, mixes, the polyaminoacid antibacterial gel for treating wound repair is made.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.50%th, 99.20%, cytotoxicity is 0 grade.
Embodiment 16
Polyaminoacid antibacterial gel component is constituted：
| Component | Weight ratio/% |
| Polyaminoacid | 10 |
| Polyvinylpyrrolidone | 10 |
| Tween | 2 |
| Sorbierite | 15 |
| Purified water | Surplus |
Polyaminoacid structure：
The preparation method of polyaminoacid antibacterial gel of the present invention, comprises the following steps：
(1) polyaminoacid is dissolved in purified water；
(2) polyvinylpyrrolidone, tween and sorbierite are dissolved in purified water；
(3) solution for obtaining step (1) and (2) is mixed, and the polyaminoacid antibacterial for treating mouth infection is made and coagulates
Glue.
To the antibacterial gel establishing criteria GB15979-2002 obtained in the present embodiment《Disposable Sanitary Accessory health
Standard》Anti-microbial property test is carried out, test is Escherichia coli, staphylococcus aureus with bacterium；Establishing criteria GB/T 16886.5-
The part of 2003 BiologicalEvaluationofMedicalDevice the 5th：Vitro cytotoxicity test carries out cytotoxicity test, and (cell is L929 mouse
Fibroblast).
After tested, the antibacterial gel obtained in the present embodiment is respectively to Escherichia coli, staphylococcus aureus
99.45%th, 99.12%, cytotoxicity is 0 grade.
Comparative example 1
Embodiment 1 is repeated, it the difference is that only, use oligomerization ammonia made from Chinese patent application CN105694030A
Base acid replaces the polyaminoacid in embodiment 1, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
78.12%th, 75.00%.
Comparative example 2
Embodiment 3 is repeated, it the difference is that only, use oligomerization ammonia made from Chinese patent application CN105694030A
Base acid replaces the polyaminoacid in embodiment 3, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
82.55%th, 80.81%.
Comparative example 3
Embodiment 5 is repeated, it the difference is that only, use oligomerization ammonia made from Chinese patent application CN105694030A
Base acid replaces the polyaminoacid in embodiment 5, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
78.33%th, 71.69%.
Comparative example 4
Embodiment 6 is repeated, it the difference is that only, use oligomerization ammonia made from Chinese patent application CN105694030A
Base acid replaces the polyaminoacid in embodiment 6, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
82.98%th, 79.84%.
Comparative example 5
Embodiment 7 is repeated, it the difference is that only, use oligomerization ammonia made from Chinese patent application CN105694030A
Base acid replaces the polyaminoacid in embodiment 7, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
86.45%th, 80.12%.
Comparative example 6
Embodiment 9 is repeated, it the difference is that only, use oligomerization ammonia made from Chinese patent application CN105694030A
Base acid replaces the polyaminoacid in embodiment 9, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
82.67%th, 80.00%.
Comparative example 7
Embodiment 11 is repeated, it the difference is that only, use oligomerization made from Chinese patent application CN105694030A
Amino acid replaces the polyaminoacid in embodiment 11, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
80.54%th, 75.32%.
Comparative example 8
Embodiment 13 is repeated, it the difference is that only, use oligomerization made from Chinese patent application CN105694030A
Amino acid replaces the polyaminoacid in embodiment 13, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
84.20%th, 79.52%.
Comparative example 9
Embodiment 15 is repeated, it the difference is that only, use oligomerization made from Chinese patent application CN105694030A
Amino acid replaces the polyaminoacid in embodiment 15, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
87.35%th, 83.21%.
Comparative example 10
Embodiment 16 is repeated, it the difference is that only, use oligomerization made from Chinese patent application CN105694030A
Amino acid replaces the polyaminoacid in embodiment 16, and oligomeric amino acid structure is as follows made from CN105694030A：
After tested, the antibacterial gel obtained in this comparative example is respectively to Escherichia coli, staphylococcus aureus
89.95%th, 85.44%.
Obviously, the above embodiment of the present invention is only intended to clearly illustrate example of the present invention, and is not pair
The restriction of embodiments of the present invention.For those of ordinary skill in the field, may be used also on the basis of the above description
To make other changes in different forms.Here all embodiments can not be exhaustive.It is every to belong to this hair
Row of the obvious changes or variations that bright technical scheme is extended out still in protection scope of the present invention.
Claims (10)
1. a kind of polyaminoacid antibacterial gel, it is characterised in that polyaminoacid antibacterial gel includes the group of following percentage by weight
Point：0.01-50% polyaminoacid, 0.01-90% gel-type vehicles, 0-20% NMFs, 0-1% preservative agents, surplus is water.
2. polyaminoacid antibacterial gel according to claim 1, it is characterised in that the polyaminoacid is such as following formula (I)
Structure：
It is abbreviated as R- [(M)m-(N)n]z,
In formula (I), R is any one in structure as shown below：
In formula (I), R1For any one in structure as shown below：
In formula (I), R2For any one in structure as shown below：
In formula (I), m and n are respectively polyaminoacid repeat unit M and repeat unit N number of repeat unit；Z is (M) m- (N) n's
Number of repeat unit；M, n, z are positive integer, m=5-10000, n=0-1000, z=1-100；" * " is R, R1、R2It is adjacent thereto
The chemical bond chalaza of group.
3. polyaminoacid antibacterial gel according to claim 2, it is characterised in that work as R2To be any in structure as shown below
When a kind of：
Then m × z ＞ 50% (m × z+n × z)；
That is, repeat unit M sum is more than the 50% of repeat unit M and repeat unit N summations.
4. polyaminoacid antibacterial gel according to claim 1 or claim 2, it is characterised in that：The polyaminoacid is in polyaminoacid
Percentage by weight in antibacterial gel is 0.1-50%, or 1-50%, or 5-50%, or 10-50%, or 15-50%, or 20-
50%, or 25-50%, or 30-50%, or 35-50%, or 40-50%, or 45-50%, or 0.1-40%, or 1-40%, or
5-40%, or 15-40%, or 20-40%, or 25-40%, or 30-40%, or 35-40%, or 0.1-30%, or 1-30%,
Or 5-30%, or 10-30%, or 15-30%, or 20-30%, or 25-30%, or 0.1-20%, or 1-20%, or 5-
20%, or 10-20%, or 15-20%, or 0.1-10%, or 1-10%, or 5-10%.
5. polyaminoacid antibacterial gel according to claim 1 or claim 2, it is characterised in that：The gel-type vehicle be selected from carbomer,
It is Chitosan-phospholipid complex, alginic acid and its salt, trehalose, hyaluronic acid and its salt, cellulose derivative, xanthans, bright
One in glue, collagen, carragheen, Arabic gum, flaxseed gum, Polycarbophil, polyvinylpyrrolidone and polyvinyl alcohol
Plant or a variety of；
Preferably, percentage by weight of the gel-type vehicle in polyaminoacid antibacterial gel is 0.1-90%, or 0.1-80%,
0.1-70%, 0.1-60%, 0.1-50%, 0.1-40%, 0.1-30%, 0.1-20%, 0.1-10%, 0.1-5%, 0.5-
90%, 0.5-80%, 0.5-70%, 0.5-60%, 0.5-50%, 0.5-40%, 0.5-30%, 0.5-20%, 0.5-10%,
0.5-5%.
6. polyaminoacid antibacterial gel according to claim 1 or claim 2, it is characterised in that：The NMF is selected from glycerine, sorb
One or more in alcohol, propane diols, butanediol, pentanediol, glycerine and n-butanol；
Preferably, percentage by weight of the NMF in polyaminoacid antibacterial gel is 1-20%, or 1-18%, or 1-
16%, or 1-14%, or 1-12%, or 3-20%, or 3-18%, or 3-16%, or 3-14%, or 3-12%, or 5-20%,
Or 5-18%, or 5-16%, or 5-14%, or 5-12%, or 7-20%, or 7-18%, or 7-16%, or 7-14%, or 7-
12%, or 9-20%, or 9-18%, or 9-16%, or 9-14%, or 9-12%.
7. polyaminoacid antibacterial gel according to claim 1 or claim 2, it is characterised in that：The preservative agent is selected from ethylenediamine tetraacetic
Acetic acid disodium, sodium benzoate, potassium sorbate, citric acid, ethyl hydroxy benzoate, methyl para Toluic Acid, parabens and its
One or more in sodium salt, the golden ethyl ester of Nepal；
Preferably, percentage by weight of the preservative agent in polyaminoacid antibacterial gel is 0.1-1%, or 0.1-0.9%, or
0.1-0.8%, or 0.1-0.7%, or 0.1-0.6%, or 0.3-0.9%, or 0.3-0.8%, or 0.3-0.7%, or 0.3-
0.6%, or 0.4-0.9%, or 0.4-0.8%, or 0.4-0.7%, or 0.4-0.6%.
8. polyaminoacid antibacterial gel according to claim 1 or claim 2, it is characterised in that：In the polyaminoacid antibacterial gel
Other additives can also be included；
Preferably, other additives include one kind or many in nutritional agents, solubilizer, pH adjusting agent and osmotic pressure regulator
Kind；
Preferably, the nutritional agents be selected from fibroblast growth factor, epithelical cell growth factor, platelet derived growth because
One or more in son, collagen and allantoin；Preferably, nutritional agents weight hundred in polyaminoacid antibacterial gel
Divide than being 0.003-0.007%；
Preferably, the solubilizer is selected from polyethylene glycol, poloxamer, tween, polyoxyethylene wool alcohol ether, lauryl alcohol polyoxy second
One or more in alkene ether, polyacrylic acid glycerol ester and ethanol；Preferably, the solubilizer is in polyaminoacid antibacterial gel
Percentage by weight is 0.04-0.06%；
Preferably, the pH adjusting agent is selected from alkaline conditioner and acid regulator；Wherein, alkaline conditioner be triethanolamine,
One or more in sodium hydroxide and sodium citrate, acid regulator be hydrochloric acid, acetic acid, lactic acid and citric acid in one kind or
It is a variety of, it is preferable that alkaline matter percentage by weight in polyaminoacid antibacterial gel is 0.1-0.3%, and acidic materials exist
Percentage by weight is 0.8-1.2% in polyaminoacid antibacterial gel；
Preferably, one or more of the osmotic pressure regulator in sodium chloride, boric acid and borax；Preferably, it is described to ooze
Pressure conditioning agent percentage by weight in polyaminoacid antibacterial gel is 0.8-1.2% thoroughly.
9. polyaminoacid antibacterial gel according to claim 1 or claim 2, it is characterised in that：The water is purified water.
10. any one of the as described above preparation method of the polyaminoacid antibacterial gel described in claim, it is characterised in that including such as
Lower step：
S1, polyaminoacid is dissolved in purified water；
S2, gel-type vehicle, NMF, preservative agent and other additives are mixed with purifying after water-swellable dissolving respectively, then will step
The polyaminoacid solution that rapid S1 is obtained is mixed with it, and polyaminoacid antibacterial gel of the present invention is made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710450875.5A CN107028875A (en) | 2017-06-15 | 2017-06-15 | A kind of antibacterial polyaminoacid gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710450875.5A CN107028875A (en) | 2017-06-15 | 2017-06-15 | A kind of antibacterial polyaminoacid gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107028875A true CN107028875A (en) | 2017-08-11 |
Family
ID=59542140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710450875.5A Pending CN107028875A (en) | 2017-06-15 | 2017-06-15 | A kind of antibacterial polyaminoacid gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107028875A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568652A (en) * | 2018-12-26 | 2019-04-05 | 粤肽生物科技(珠海)有限公司 | Promote the dressing composition of wound healing |
| CN111249176A (en) * | 2020-02-21 | 2020-06-09 | 华熙生物科技股份有限公司 | No-clean disinfectant, preparation method and application thereof |
| CN111494306A (en) * | 2020-05-29 | 2020-08-07 | 杭州百芮生物科技有限公司 | Female private gel microecological preparation composition and preparation method thereof |
| CN112316195A (en) * | 2020-10-30 | 2021-02-05 | 苏州度博迈医疗科技有限公司 | Preparation method of loofah sponge antibacterial dressing |
| CN112868910A (en) * | 2021-01-27 | 2021-06-01 | 张才来 | Preparation method and application of feed additive for improving quality of live pigs |
| CN116726241A (en) * | 2023-08-11 | 2023-09-12 | 江苏亨瑞生物医药科技有限公司 | Collagen hemostatic and antibacterial dressing and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784103A (en) * | 2015-03-31 | 2015-07-22 | 青岛科技大学 | Injectable antibacterial hydrogel based on amphiphilic molecules of oligomeric amino acid |
| WO2016161372A1 (en) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
-
2017
- 2017-06-15 CN CN201710450875.5A patent/CN107028875A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784103A (en) * | 2015-03-31 | 2015-07-22 | 青岛科技大学 | Injectable antibacterial hydrogel based on amphiphilic molecules of oligomeric amino acid |
| WO2016161372A1 (en) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
Non-Patent Citations (1)
| Title |
|---|
| 中国轻工集团生活用纸技术中心: "《中国生活用纸年鉴》", 31 December 2005, 中国石化出版社 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568652A (en) * | 2018-12-26 | 2019-04-05 | 粤肽生物科技(珠海)有限公司 | Promote the dressing composition of wound healing |
| CN111249176A (en) * | 2020-02-21 | 2020-06-09 | 华熙生物科技股份有限公司 | No-clean disinfectant, preparation method and application thereof |
| CN111494306A (en) * | 2020-05-29 | 2020-08-07 | 杭州百芮生物科技有限公司 | Female private gel microecological preparation composition and preparation method thereof |
| CN112316195A (en) * | 2020-10-30 | 2021-02-05 | 苏州度博迈医疗科技有限公司 | Preparation method of loofah sponge antibacterial dressing |
| CN112316195B (en) * | 2020-10-30 | 2022-06-14 | 苏州度博迈医疗科技有限公司 | Preparation method of loofah sponge antibacterial dressing |
| CN112868910A (en) * | 2021-01-27 | 2021-06-01 | 张才来 | Preparation method and application of feed additive for improving quality of live pigs |
| CN116726241A (en) * | 2023-08-11 | 2023-09-12 | 江苏亨瑞生物医药科技有限公司 | Collagen hemostatic and antibacterial dressing and preparation method thereof |
| CN116726241B (en) * | 2023-08-11 | 2023-10-20 | 江苏亨瑞生物医药科技有限公司 | Collagen hemostatic and antibacterial dressing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107028875A (en) | A kind of antibacterial polyaminoacid gel and preparation method thereof | |
| CN110448722B (en) | An injectable temperature-sensitive composite antibacterial hydrogel material containing tannic acid and its preparation and application | |
| CN115124738B (en) | A double-layer biomimetic drug-loaded hydrogel and its preparation and application | |
| JP6768705B2 (en) | Compositions for wound dressings | |
| CN1320931C (en) | Polyvinyl alcohol hydrogel dressing containing medicine and chitosan and preparation method thereof | |
| US6379702B1 (en) | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives | |
| WO2019022493A1 (en) | Wound dressing comprising hyaluronic acid-calcium and polylysine and manufacturing method therefor | |
| CN103930133A (en) | In situ crosslinkable polymer composition and method thereof | |
| JP2019206596A (en) | Compositions and uses of antimicrobial materials with tissue-compatible properties | |
| EP1280857A1 (en) | Wound gels | |
| CN106563156A (en) | Gel wound dressing having film-forming property | |
| EP1901786B1 (en) | Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process | |
| WO2021128050A1 (en) | Hemostatic paste and uses thereof | |
| CN104586753A (en) | Carboxymethyl chitosan antibacterial film spray and preparation method thereof | |
| CN1850291A (en) | Liquid wound-dressing with functions of promoting heal of wound and bacterial-resisting | |
| CN115850733B (en) | An injectable nanoclay hydrogel and its preparation method and application | |
| WO2011004399A2 (en) | Liquid filmogenic chitosan skin for wound healing and a method for preparation thereof | |
| Fletes-Vargas et al. | Natural hydrogels as wound dressing for skin wound-healing applications | |
| WO2011100935A1 (en) | Dry material of hydrogel for wound dressing and its method of preparation | |
| CN111012944A (en) | Liquid dressing based on alginate and hyaluronic acid and preparation method thereof | |
| TWI499436B (en) | Fiber-forming hydrogel composition and preparation method | |
| CN107982568A (en) | Degradable biological auxiliary material and its preparation method and application | |
| EP3532026A1 (en) | Nanotechnology-based hemostatic dressings | |
| JPH1085318A (en) | Medical material and skin ulcer filling/recovering material | |
| KR20110023399A (en) | Intelligent fibrin bioadhesive with excellent hemostatic effect and mechanical properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170811 |
|
| RJ01 | Rejection of invention patent application after publication |